{"created":"2023-11-15T07:18:27.488738+00:00","id":2000422,"links":{},"metadata":{"_buckets":{"deposit":"59f22aa7-1360-445b-8000-436c051d9e8b"},"_deposit":{"created_by":42,"id":"2000422","owners":[42],"pid":{"revision_id":0,"type":"depid","value":"2000422"},"status":"published"},"_oai":{"id":"oai:kindai.repo.nii.ac.jp:02000422","sets":["14:2667:1697004343623"]},"author_link":[],"item_1693381679919":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"report","resourceuri":"http://purl.org/coar/resource_type/c_93fc"}]},"item_30001_bibliographic_information17":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicNumberOfPages":"5","bibliographic_titles":[{"bibliographic_title":"科学研究費助成事業研究成果報告書 (2022)","bibliographic_titleLang":"ja"}]}]},"item_30001_creator2":{"attribute_name":"研究代表者","attribute_type":"creator","attribute_value_mlt":[{"creatorAffiliations":[{"affiliationNameIdentifiers":[{"affiliationNameIdentifier":"34419","affiliationNameIdentifierScheme":"kakenhi"}],"affiliationNames":[{"affiliationName":"近畿大学","affiliationNameLang":"ja"},{"affiliationName":"Kindai University","affiliationNameLang":"en"}]}],"creatorNames":[{"creatorName":"坂野, 恵里","creatorNameLang":"ja"},{"creatorName":"Banno, Eri","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"60580793","nameIdentifierScheme":"e-Rad"}]}]},"item_30001_description8":{"attribute_name":"内容記述","attribute_value_mlt":[{"subitem_description":"前立腺癌細胞株において、他癌腫で認めるようなTp53変異の有無によるHDAC阻害剤(vorinostat, entinostat)の感受性の違いは認めなかった。前立腺癌マウスモデルにおいては、HDAC阻害剤は抗腫瘍効果を示し、腫瘍関連マクロファージや制御性T細胞、骨髄由来抑制細胞の各関連遺伝子の発現低下を認めた一方で、抗腫瘍作用を有するCD8陽性T細胞関連遺伝子の発現は低下していた。抗PD-1抗体およびHDAC阻害剤の併用投与群は、抗PD-1抗体単独投与群に比し、腫瘍組織におけるCD8細胞陽性細胞数や制御性T細胞数に差を認めなかった。","subitem_description_language":"ja","subitem_description_type":"Abstract"},{"subitem_description":"In prostate cancer cell lines, there was no significant difference in sensitivity to HDAC inhibitors (vorinostat, entinostat) depending on Tp53 mutation. In mouse models of prostate cancer, a HDAC inhibitor vorinostat showed the antitumor effect, downregulating expression of genes associated with tumor-associated macrophages, regulatory T cells, and bone marrow-derived suppressor cells, while downregulating expression of genes associated with anti-tumor cytotoxic CD8+ cells. No significant difference was observed in the number of tumor-infiltrating CD8+ T cells and regulatory T cells between the combination therapy (HDAC inhibitor and anti-PD-1 antibody) and the monotherapy of anti-PD-1 antibody.","subitem_description_language":"en","subitem_description_type":"Abstract"},{"subitem_description":"研究分野：泌尿器腫瘍学","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_30001_file22":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","filename":"20K18104seika.pdf","format":"application/pdf","mimetype":"application/pdf","url":{"url":"https://kindai.repo.nii.ac.jp/record/2000422/files/20K18104seika.pdf"},"version_id":"4bac24e9-665e-43a2-966a-a61e562de9ce"}]},"item_30001_funding_reference15":{"attribute_name":"助成情報","attribute_value_mlt":[{"subitem_award_numbers":{"subitem_award_number":"20K18104","subitem_award_uri":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-20K18104/"},"subitem_award_titles":[{"subitem_award_title":"前立腺癌におけるHDAC阻害剤の免疫調節作用および免疫複合療法への応用の研究","subitem_award_title_language":"ja"},{"subitem_award_title":"Immunomodulatory effects of HDAC inhibitors for combination immunotherapy in prostate cancer","subitem_award_title_language":"en"}],"subitem_funder_names":[{"subitem_funder_name":"独立行政法人日本学術振興会","subitem_funder_name_language":"ja"},{"subitem_funder_name":"Japan Society for the Promotion of Science","subitem_funder_name_language":"en"}]}]},"item_30001_language10":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_30001_subject7":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"前立腺癌","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"HDAC阻害剤","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"複合免疫療法","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"腫瘍免疫微小環境","subitem_subject_language":"ja","subitem_subject_scheme":"Other"},{"subitem_subject":"TP53変異","subitem_subject_language":"ja","subitem_subject_scheme":"Other"}]},"item_30001_title0":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"前立腺癌におけるHDAC阻害剤の免疫調節作用および免疫複合療法への応用の研究","subitem_title_language":"ja"},{"subitem_title":"Immunomodulatory effects of HDAC inhibitors for combination immunotherapy in prostate cancer","subitem_title_language":"en"}]},"item_30001_version_type12":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_title":"前立腺癌におけるHDAC阻害剤の免疫調節作用および免疫複合療法への応用の研究","item_type_id":"40001","owner":"42","path":["1697004343623"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2023-11-15"},"publish_date":"2023-11-15","publish_status":"0","recid":"2000422","relation_version_is_last":true,"title":["前立腺癌におけるHDAC阻害剤の免疫調節作用および免疫複合療法への応用の研究"],"weko_creator_id":"42","weko_shared_id":-1},"updated":"2024-10-23T00:48:15.835580+00:00"}